Mumps - Pipeline Review, H2 2017 - Product Image

Mumps - Pipeline Review, H2 2017

  • ID: 4334000
  • Report
  • 32 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Sinovac Biotech Ltd
  • MORE
Mumps - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Mumps - Pipeline Review, H2 2017, provides an overview of the Mumps (Infectious Disease) pipeline landscape.

Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus. The virus is spread from person-to-person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Mumps - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 1, 1, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mumps (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Sinovac Biotech Ltd
  • MORE
Introduction

Mumps - Overview

Mumps - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mumps - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Mumps - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Daiichi Sankyo Company Ltd

GlaxoSmithKline Plc

Sinovac Biotech Ltd

Zydus Cadila Healthcare Ltd

Mumps - Drug Profiles

(measles + mumps + rubella + varicella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mumps vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mumps vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mumps vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VN-0102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mumps - Dormant Projects

Mumps - Product Development Milestones

Featured News & Press Releases

Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Mumps, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Mumps - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2

Mumps - Pipeline by Daiichi Sankyo Company Ltd, H2

Mumps - Pipeline by GlaxoSmithKline Plc, H2

Mumps - Pipeline by Sinovac Biotech Ltd, H2

Mumps - Pipeline by Zydus Cadila Healthcare Ltd, H2

Mumps - Dormant Projects, H2

List of Figures

Number of Products under Development for Mumps, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • Daiichi Sankyo Company Ltd
  • GlaxoSmithKline Plc
  • Sinovac Biotech Ltd
  • Zydus Cadila Healthcare Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll